SCHEMBL1714146

SCHEMBL1714146

CCCSC1=NC(=Cc2c[nH]c3ncc(Cl)cc23)C(=O)N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK2 Q92630 3/20 0.45
▸ DYRK3 O43781 2/20 0.45
▸ PIM1 P11309 2/20 0.45
▸ CSNK2A2 P19784 2/20 0.45
▸ CSNK2B P67870 2/20 0.45
▸ CSNK2A1 P68400 2/20 0.45
▸ DYRK1A Q13627 2/20 0.45
▸ CSNK2A3 Q8NEV1 2/20 0.45
▸ DYRK1B Q9Y463 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.39
▸ GPR18 Q14330 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ CNR1 P21554 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ BRAF P15056 3/20 0.33
▸ BMPR1B O00238 1/20 0.32
▸ PLK4 O00444 1/20 0.32
▸ PIR O00625 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714145 1.00 DYRK2 (0.45) DYRK2DYRK3PIM1CSNK2A2CSNK2B
SCHEMBL1714289 0.86 GPR18 (0.43) DYRK2DYRK3PIM1CSNK2A2CSNK2B
SCHEMBL1714283 0.86 GPR18 (0.43) DYRK2DYRK3PIM1CSNK2A2CSNK2B
SCHEMBL1714322 0.84 GPR18 (0.45) CSNK2BKDM4EGPR18JAK2CNR1
SCHEMBL1714325 0.84 GPR18 (0.45) CSNK2BKDM4EGPR18JAK2CNR1
SCHEMBL1714505 0.83 JAK2 (0.34) KDM4EGPR18HPGDJAK2CNR1
SCHEMBL1714502 0.83 JAK2 (0.34) KDM4EGPR18HPGDJAK2CNR1
SCHEMBL1714259 0.80 JAK2 (0.34) DYRK2JAK2BRAFBMPR1BPLK4
SCHEMBL1714261 0.80 JAK2 (0.34) DYRK2JAK2BRAFBMPR1BPLK4
SCHEMBL1714488 0.78 JAK2 (0.36) JAK2BRAFCHEK1CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 — — US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 — — EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 — — US disclosed
EP-2094699-A2 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 Sanofi-Aventis (FR) 2009-09-02 — — EP disclosed
WO-2008046982-A2 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2008-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 DYRK2 792/4885DYRK3 1123/4885PIM1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback